Analyses / MRNA
Large-cap biotech after a sharp 52-week drawdown. Revenue is contracting and losses are large. Event-driven read with limited fundamental data.
A free account reveals MRNA's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
If the cancer therapy filing stays on its year-end timeline and the stock holds above the 196.52 day low, the setup could attract renewed interest. Current ratio of 3.29 gives balance-sheet liquidity room. Price-to-FCF of 17.5x is below what a stressed name might carry, and the stock sits about 30% under its 52-week high of 280.8. Stock reportedly rose on the cancer data before a sharp reversal, so sentiment could improve if the pipeline story gains traction.
▼ Bear Case
Revenue fell 53.44% and operating margin is -158.13%, so the business is shrinking while losing money. Insider activity skews to selling (150 sell vs 102 buy transactions; 3.59M shares sold vs 3.32M bought). Price-to-sales of 41.3x leaves little room for disappointment. Headlines show the stock fell despite positive cancer data, which may point to skepticism about commercial revenue. A break below the 196.52 day low opens a move toward the 52-week low zone.
Valuation
stretched on sales, unclear on earnings — score 35/100
Multiples that rely on earnings are null or negative. Price-to-sales is very high against a shrinking revenue base.
Technical Levels
Support · $196.52 (Today's day low) · $22.28 (52-week low (distant reference))
Resistance · $206.80 (Prev close / open) · $208.68 (Today's day high) · $280.80 (52-week high)
RSI: unavailable
Financial Health
Score 55/100. Liquidity ratios look comfortable. Leverage and coverage data are missing, so solvency cannot be fully assessed.
Catalysts
| Cancer therapy regulatory filing (per headline, targeted by year-end) | Year-end (per news headline) | high |
| Market reaction to cancer vaccine data, which lifted results but drove the stock lower | Recent (per news) | medium |
| Ongoing insider selling activity | Continuous (per provider insider data) | low |
Risk Flags
See MRNA's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock MRNA free →Recent News
- While Moderna sank 17%, this generic drugmaker quietly jumped 64%Yahoo
- Moderna (MRNA) Dropped, So What Is Behind The Latest Attention?Yahoo
- Moderna's Cancer Vaccine Worked, and the Stock Plunged Anyway. Here's What Investors Are Missing.Yahoo
- Global Medical Countermeasures Market 2026: Size, Trends, and Forecast to 2030 | Capitalize on AI, Stockpiling, and Rapid Diagnostics with Pfizer, Moderna, Sanofi, and EmergentYahoo
- Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?Yahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full MRNA analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
MRNA FAQ
Is MRNA a buy right now?
Moderna, Inc.'s current read is a Event-driven recovery watch setup with low confidence over a 3m horizon. Valuation: stretched on sales, unclear on earnings. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is MRNA overvalued?
stretched on sales, unclear on earnings (valuation score 35/100). Multiples that rely on earnings are null or negative. Price-to-sales is very high against a shrinking revenue base.
What are the risks of buying MRNA?
Revenue fell 53.44% and operating margin is -158.13%, so the business is shrinking while losing money. Insider activity skews to selling (150 sell vs 102 buy transactions; 3.59M shares sold vs 3.32M bought). Price-to-sales of 41.3x leaves little room for disappointment. Headlines show the stock fell despite positive cancer data, which may point to skepticism about commercial revenue. A break below the 196.52 day low opens a move toward the 52-week low zone.